乳腺癌区域淋巴结照射后淋巴水肿的风险器官确定
本研究回顾性分析265例II-III期乳腺癌接受区域淋巴结照射的患者,将腋窝分为8个亚区并分析剂量-体积与淋巴水肿的关系。发现腋窝-胸外侧血管交界处(ALTJ)最低剂量<38.6 Gy与3年淋巴水肿率显著降低相关(5.7% vs 37.4%,P<.001),且不影响淋巴结覆盖。
要点
- ALTJ最低剂量<38.6 Gy与淋巴水肿风险降低独立相关(HR 0.13)。
- ALTJ Dmin<38.6 Gy时锁骨上、III、II、I站淋巴结V45Gy中位数保持高位。
- BMI和淋巴结清扫数目也是淋巴水肿的显著预测因素。
核心结论
- 腋窝-胸外侧血管交界处(ALTJ)可能是乳腺癌放疗中淋巴水肿的风险器官,避免其高剂量照射可在不显著牺牲淋巴结覆盖的情况下降低淋巴水肿风险。
研究设计与样本
- 回顾性队列研究,纳入2013-2017年接受乳腺手术联合腋窝评估及区域淋巴结照射的265例II-III期乳腺癌女性,淋巴结靶区按RTOG指南前瞻性勾画,腋窝8个亚区回顾性勾画,淋巴水肿通过臂围评估,采用多因素Cox回归分析预测因素。
主要发现
- 中位放疗后随访3年(IQR 1.9-3.6),ALTJ剂量与淋巴水肿风险最相关(maximally selected rank statistic=6.3,P<.001)。
- ALTJ最低剂量(Dmin)<38.6 Gy组3年淋巴水肿率为5.7%,≥38.6 Gy组为37.4%(P<.001)。
- 多因素分析显示ALTJ Dmin<38.6 Gy(HR 0.13;P<.001)、BMI(HR 1.06/单位;P=.002)和淋巴结清扫数目(HR 1.08/枚;P<.001)是显著预测因素。
- ALTJ Dmin<38.6 Gy的患者中,锁骨上、III站、II站、I站淋巴结V45Gy中位数分别为99%(IQR 94-100%)、100%(IQR 97%-100%)、98%(IQR 86-100%)、91%(IQR 75-98%)。
关键数值与推荐
- ALTJ Dmin<38.6 Gy为降低淋巴水肿风险的候选剂量学指标,对应3年淋巴水肿率5.7% vs 37.4%(P<.001)。
- 避免ALTJ高剂量时,淋巴结 basin 的V45Gy中位数保持在较高水平(锁骨上99%、III站100%、II站98%、I站91%)。
临床怎么用
- 在乳腺癌区域淋巴结照射计划中,可考虑将ALTJ作为剂量限制性风险器官,尝试使ALTJ Dmin<38.6 Gy,同时评估淋巴结覆盖是否充分。
- 对BMI较高或淋巴结清扫数目较多的患者,应更关注淋巴水肿风险,优化ALTJ照射剂量。
局限性
- 本研究为回顾性分析,ALTJ亚区为回顾性勾画,需要未来前瞻性研究确认。
- 淋巴水肿通过臂围评估,随访中位时间3年,可能低估晚期淋巴水肿发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lymphedema after regional nodal irradiation is a severe complication that could be minimized without significantly compromising nodal coverage if the anatomic region(s) associated with lymphedema were better defined. This study sought to correlate dose-volume relationships within subregions of the axilla with lymphedema outcomes to generate treatment planning guidelines for reducing lymphedema risk. METHODS AND MATERIALS: Women with stage II-III breast cancer who underwent breast surgery with axillary assessment and regional nodal irradiation were identified. Nodal targets were prospectively contoured per Radiation Therapy Oncology Group guidelines for field design. The axilla was divided into 8 distinct subregions that were retrospectively contoured. Lymphedema outcomes were assessed by arm circumferences. Multivariate Cox proportional hazards regression assessed patient, surgical, and dosimetric predictors of lymphedema outcomes. RESULTS: Treatment planning computed tomography scans for 265 women treated between 2013 and 2017 were identified. Median post-radiation therapy follow-up was 3 years (interquartile range [IQR], 1.9-3.6). Dose to the axillary-lateral thoracic vessel juncture (ALTJ; superior to level I) was most associated with lymphedema risk (maximally selected rank statistic = 6.3, P < .001). The optimal metric was ALTJ minimum dose (Dmin) <38.6 Gy (3-year lymphedema rate 5.7% vs 37.4%, P <.001), although multiple parameters relating to sparing of the ALTJ were highly correlated. Multivariate analysis confirmed ALTJ Dmin <38.6 Gy (hazard ratio [HR], 0.13; P < .001), body mass index (HR, 1.06/unit; P = .002), and number of lymph nodes removed (HR, 1.08/node; P < .001) as significant predictors. Women with ALTJ Dmin <38.6 Gy maintained median V45Gy of 99% in the supraclavicular (IQR, 94-100%), 100% in level III (IQR, 97%-100%), 98% in level II (IQR, 86%-100%), and 91% in level I (IQR, 75%-98%) nodal basins. CONCLUSIONS: Anatomic studies suggest the ALTJ region is typically traversed by arm lymphatics and appears to be an organ at risk in breast radiation therapy. Ideally, avoidance of the ALTJ may be feasible while simultaneously encompassing breast-draining nodal basins. Confirmation of this finding in future prospective studies is needed.
引用
- Gross JP, Lynch CM, Flores AM, et al. Determining the Organ at Risk for Lymphedema After Regional Nodal Irradiation in Breast Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31260718. doi:10.1016/j.ijrobp.2019.06.2509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。